Examkin

Question

Difficulty: MediumRheumatology and Immunology

During a routine follow-up evaluation, a 32-year-old woman with diffuse cutaneous systemic sclerosis reports severe pain and discoloration in her digits. She notes that exposure to cold temperatures triggers her fingers to turn sharply white, then blue, and finally red. Arrange the following therapeutic interventions in the correct step-wise sequence for the management of this patient's Raynaud phenomenon, proceeding from initial conservative measures to therapies reserved for severe, refractory, or tissue-threatening disease.

  1. 1Implementation of strict cold avoidance, extremity warming, and smoking cessation
  2. 2Initiation of an oral dihydropyridine calcium channel blocker (e.g., nifedipine)
  3. 3Addition of a phosphodiesterase-5 inhibitor (e.g., sildenafil)
  4. 4Administration of an intravenous prostanoid analog (e.g., iloprost)

Answer

The correct sequence for managing secondary Raynaud phenomenon is: non-pharmacologic lifestyle modifications, followed by oral calcium channel blockers, followed by phosphodiesterase-5 inhibitors, and finally intravenous prostanoids for severe tissue-threatening disease.
The standard of care for secondary Raynaud phenomenon involves a precise step-wise escalation. It begins unconditionally with conservative lifestyle modifications, primarily avoiding cold triggers, ensuring whole-body warming, and smoking cessation. If these measures fail to adequately control the frequency or severity of attacks, first-line medical therapy is initiated with dihydropyridine calcium channel blockers (such as nifedipine or amlodipine). Should the patient remain highly symptomatic despite maximally tolerated doses of CCBs, second-line oral agents such as phosphodiesterase-5 inhibitors (e.g., sildenafil) or topical nitrates are added. Finally, for severe, refractory cases presenting with critical digital ischemia or active digital ulcerations, advanced therapies like intravenous prostanoid analogs (iloprost) or endothelin receptor antagonists (bosentan) are utilized.

Step-by-Step Solution

1
Identify the primary clinical presentation.
The patient is presenting with classic triphasic color changes indicative of Raynaud phenomenon, secondary to systemic sclerosis.
Accurate identification of the syndrome dictates the appropriate treatment algorithm.
2
Determine the first-line conservative management.
Cold avoidance and smoking cessation.
All patients must begin with non-pharmacologic lifestyle modifications to minimize triggers before initiating medications.
3
Select the first-line pharmacologic therapy.
Dihydropyridine calcium channel blockers (e.g., nifedipine or amlodipine).
Calcium channel blockers are the standard initial medical therapy for symptomatic relief if lifestyle changes are inadequate.
4
Determine the step-up therapy for refractory symptoms.
Phosphodiesterase-5 inhibitors (e.g., sildenafil).
These agents promote further vasodilation and are indicated when calcium channel blockers alone fail to control symptoms.
5
Identify the intervention for severe, critical ischemia.
Intravenous prostanoids (e.g., iloprost or epoprostenol).
Because of significant side effects and required inpatient administration, these agents are strictly reserved for severe complications like digital ulcers.

Key Concept

Step-wise escalation of therapy for secondary Raynaud phenomenon.
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic